Streetbeat News

Products Services

ADIL

Adial Pharmaceuticals has advanced to the second cohort in its pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. This progress marks a significant step in the development of the drug.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:00 pm

MESO

Mesoblast shares are trading higher after the company announced that the FDA accepted its Biologics License Application resubmission for Ryoncil in the treatment of children with steroid-refractory acute graft versus host disease.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 11:59 am

SDA

SunCar Technology has partnered with Lotus Technology to enhance its insurance services and expand its sales network.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 11:58 am

MESO

The FDA has accepted Mesoblast's Biologics License Application (BLA) for Ryoncil, a treatment for children with steroid-refractory acute graft-versus-host disease. This is a significant milestone for Mesoblast as it moves closer to potentially bringing Ryoncil to market.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 11:56 am

LI

TSLA

XIACF

XIACY

XPEV

Xiaomi has received regulatory clearance to mass-produce electric vehicles independently, marking a significant milestone in its EV ambitions. Despite production bottlenecks and quality issues, Xiaomi's SU7 model has seen strong demand. The company plans to launch more models and increase its delivery targets. However, Xiaomi faces challenges such as anti-dumping tariffs in Europe and slowing demand in China.

Portfolio Pulse from The Bamboo Works

July 23, 2024 | 11:55 am

GOOG

LYV

MUSQ

SPOT

TME

Spotify Technology (SPOT) reported strong Q2 earnings, beating analysts' expectations and showing growth in monthly active users and premium subscribers. This positive performance led to a pre-market surge in SPOT stock. The MUSQ Global Music Industry ETF (MUSQ), which includes SPOT as a top holding, may benefit from this performance. Other key holdings in MUSQ include Alphabet (GOOG), Tencent Music Entertainment Group (TME), and Live Nation Entertainment (LYV).

Portfolio Pulse from Joshenomoto@benzinga.com

July 23, 2024 | 11:50 am

CLRB

Cellectar Biosciences shares are trading lower following the announcement of results from its CLOVER WaM pivotal study evaluating iopofosine I 131.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 11:48 am

ANIX

Anixa Biosciences Inc (NASDAQ:ANIX) announced FDA approval for an individual patient trial application for its ovarian cancer CAR-T therapy. The trial, conducted in collaboration with Moffit Cancer Center, has shown promising early results. Additionally, Anixa's Board of Directors has authorized a $5 million share repurchase program, indicating confidence in the company's valuation.

Portfolio Pulse from Vandana Singh

July 23, 2024 | 11:45 am

ANIX

Anixa Biosciences reported encouraging findings of necrosis, inflammation, and T cell infiltration in a tumor biopsy of a patient in the lowest dose cohort, which could be a positive indicator for their ongoing clinical trials.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 11:45 am

ANIX

Anixa Biosciences has announced FDA approval of an Individual Patient IND for its ovarian cancer CAR-T therapy.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 11:45 am